ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.34
0.15 (6.85%)
▲
5d:
-9.65%
30d:
-29.09%
90d:
+17.0%
HOLD
LOW Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ABOS is down 5.1% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 422 OI. Call ratio: 100% View Scanner →
Strength: 7.5/10
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.34, which is considered oversold relative to its 30-day fair value range of $2.61 to $3.27.
Technical Outlook: Technically, ABOS is in a strong uptrend. Immediate support is located at $2.17, while resistance sits at $3.08. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+237.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABOS is in a strong uptrend. Immediate support is located at $2.17, while resistance sits at $3.08. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+237.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.61 -
$3.27
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.8%)
- BULLISH: Trading 237.9% below Wall St target ($7.40)
- CAUTION: Recommendation downgraded due to -9.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.61 -
$3.27
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.17
Resistance Level
$3.08
Current Trend
Strong Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.21
Wall Street Target
$7.40
(+237.9%)
Share & Embed Analysis
Last updated: March 31, 2026 2:40 PM ET
Data refreshes hourly during market hours. Next update: 3:40 PM
Data refreshes hourly during market hours. Next update: 3:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Siemers
SELL
895 shares
2026-01-22
Matt Zuga
SELL
1687 shares
2026-01-22
Russell Barton
SELL
462 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 66 BUY |
